Acumen Pharmaceuticals, Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax
Acumen Pharmaceuticals, Inc. (ABOS) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax of -$734.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax · last filed 2022-11-14
- Acumen Pharmaceuticals, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2022-09-30 was $0.00.
- Acumen Pharmaceuticals, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2022-06-30 was -$151.00K.
- Acumen Pharmaceuticals, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2022-03-31 was -$583.00K.
- Acumen Pharmaceuticals, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2021-12-31 was -$203.00K.
- Acumen Pharmaceuticals, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2021 was -$231.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$151.00K derived: sum of 2 quarters · filed 2022-11-14 | -$734.00K 10-Q · filed 2022-11-14 | -$937.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | -$151.00K 10-Q · filed 2022-08-15 | -$734.00K 10-Q · filed 2022-08-15 | -$937.00K derived: sum of 3 quarters · filed 2022-08-15 | -$965.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-03-31 | -$583.00K 10-Q · filed 2022-05-16 | -$786.00K derived: sum of 2 quarters · filed 2022-05-16 | -$814.00K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-12-31 | -$203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$231.00K derived: sum of 2 quarters · filed 2022-11-14 | -$231.00K 10-K · filed 2022-03-28 | |
| 2021-09-30 | -$28.00K 10-Q · filed 2022-11-14 | -$28.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |